Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Winter on Unmet Needs in Richter Transformation for Patients With CLL

June 24th 2024

Allison Winter, MD, discusses unmet needs for patients with Richter transformation from CLL.

Dr Ip on the Impact of BCMA Alternative Splicing in Lymphoma and Multiple Myeloma

June 24th 2024

Andrew Ip, MD, discusses alternative splicing of the TNFRSF17 gene, which encodes BCMA, in patients with lymphoma or multiple myeloma.

FDA Approves Crovalimab for Paroxysmal Nocturnal Hemoglobinuria

June 24th 2024

The FDA has approved crovalimab for patients 13 years of age and older with paroxysmal nocturnal hemoglobinuria and a body weight of at least 40 kg.

Dr Winer on the Rationale for the TakeAim Leukemia Trial in Mutated AML

June 21st 2024

Eric Winer, MD, discusses the rationale for the phase 1/2a TakeAim Leukemia trial of emavusertib in patients with R/R FLT3- and spliceosome-mutated AML.

Dr Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis in Hematologic Malignancies

June 21st 2024

Monzr M. Al Malki, MD, discusses outcomes with mismatched unrelated donor transplantation using post-transplant cyclophosphamide–based GVHD prophylaxis.

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr Jimenez Jimenez on PBSC from HLA-Mismatched Donors in Hematological Malignancies

June 21st 2024

Antonio Martin Jimenez Jimenez, MD, discusses conditioning therapy, PBSC from HLA-MMUD, and PTCy for GVHD prophylaxis in hematological malignancies.

Safety Data With Ponatinib in PHALLCON for Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALL

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Current Standards of Care for Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss current standards of care for the treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Prevalence and Prognosis of Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

MB-106 Shows Early Promise in BTKi-Refractory Waldenström Macroglobulinemia/LPL

June 21st 2024

MB-106 showcased a favorable safety profile and elicited responses in heavily pretreated patients with refractory Waldenström macroglobulinemia.

Dr Deininger on Long-Term Outcomes With Ponatinib in T315I-Mutant CP-CML

June 20th 2024

Michael Deininger, MD, PhD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

Dr Winter on Real-World Outcomes With Liso-Cel in Richter Transformation

June 20th 2024

Allison Winter, MD, discusses data from a retrospective analysis evaluating real-world outcomes with liso-cel in patients with Richter transformation.

Dr Hantel on Socioeconomic Influences on First-Line Treatment in AML

June 18th 2024

Andrew Hantel, MD, discusses the influence of race/ethnicity and socioeconomic status on the timeliness of first-line treatment in acute myeloid leukemia.

Dr Svoboda on the Investigation of huCART19-IL18 in Relapsed/Refractory Lymphoma

June 18th 2024

Jakub Svoboda, MD, discusses the investigation of huCART19-IL18 in patients with relapsed/refractory lymphomas that have progressed.

Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia and the T315I Mutation: 4-Year Results From OPTIC

June 18th 2024

Jorge Cortes, MD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis

June 17th 2024

Patients with essential thrombocythemia who progressed to myelofibrosis had longer duration of disease, higher white blood cell counts, and lower hemoglobin levels at enrollment.

Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL

June 16th 2024

Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.